drugset / Trial / NCT01265524

Evaluation of CLP in Heart Failure Patients With Chronic Kidney Disease

NCT01265524 ↗

Phase 2 Completed 113 enrolled Sorbent Therapeutics Pharmaterra · collab
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to determine the effects of CLP on serum potassium and signs and symptoms of fluid overload in heart failure patients with chronic kidney disease.

Timeline

Start
2011-04
Primary completion
2011-11
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Comparator CLP Unknown 15 g Oral

Indications